UPCC 08423: PHASE 2 SINGLE-ARM NON-INFERIORITY STUDY OF LIMITED-DURATION TECLISTAMAB FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
Enrolling By Invitation
99 years and younger
All
Phase
2
75 participants needed
1 Location
Brief description of study
Please refer to Protocol Section 4 Please refer to Protocol Section 4 Please refer to Protocol Section 4
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
14 Jun 2023.
Study ID: 853459
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
